Breast Cancer
Early Breast Cancer HER2+ KATHERINE Pembrolizumab - Placebo FDA theraputic indication: adjuvant treatment of adults and adolescents aged 12 years and older with Stage IIB, IIC following complete resection. EMA therapeutic indication: adjuvant treatment of adults and adolescents aged 12 years and older with stage IIB, IIC or III melanoma and who have undergone complete resection KEYNOTE-716Skin Cancers
Cutaneous Melanoma - KEYNOTE-716 Nivolumab Platinum-doublet ChT Platinum-doublet ChT Treatment of adult patients with resectable non-small cell lung cancer in the neoadjuvant setting CheckMate-816Thoracic Malignancies
Non-small-cell Lung Cancer - CheckMate-816 Selpercatinib - Single arm Treatment of adults with advanced RET fusion positive non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor LIBRETTO-001Thoracic Malignancies
Non-small-cell Lung Cancer RET fusion-positive LIBRETTO-001 Trastuzumab deruxtecan - Trastuzumab emtansine (T-DM1) Treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received one or more prior anti HER2 based regimens DESTINY-Breast03Breast Cancer
Breast Cancer HER2+ DESTINY-Breast03 Nivolumab Fluoropyrimidine + platinum-based combination ChT ChT First-line treatment of adult patients with advance or metastatic oesophageal squamous cell carcinoma in combination with fluoropyrimidine and platinum-based combination ChT CheckMate 648Gastrointestinal Cancers
Oesophageal squamous cell carcinoma - CheckMate 648 Nivolumab + ipilimumab - ChT First-line treatment of adult patients with advance or metastatic oesophageal squamous cell carcinoma in combination with ipilimumab CheckMate 648Gastrointestinal Cancers
Oesophageal squamous cell carcinoma - CheckMate 648 Dab/Tram (dabrafenib and trametinib) - Single arm (Phase II) For the treatment of adult and pediatric patients ≥ 6 years of age with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options ROARBrain Tumours
Glioma (high grade) BRAF V600E ROAR Dab/Tram (dabrafenib and trametinib) - Single arm (Phase II) For the treatment of adult and pediatric patients ≥ 6 years of age with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options ROARBrain Tumours
Glioma (low grade) BRAF V600E ROAR Dab/Tram (dabrafenib and trametinib) - Single arm Patients with locally advanced or metastatic ATC with BRAF V600E mutation and with no satisfactory locoregional treatment options ROAREndocrine Tumours
Thyroid Cancer - anaplastic BRAF V600E ROAR Dab/Tram (dabrafenib and trametinib) - Single arm (Phase II) For the treatment of adult and pediatric patients ≥ 6 years of age with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options ROARGastrointestinal Cancers
Biliary tract cancer BRAF V600E ROAR Durvalumab Gemcitabine and cisplatin Placebo + gemcitabine and cisplatin Durvalumab in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer TOPAZ-1Gastrointestinal Cancers
Biliary tract cancer - TOPAZ-1 Trastuzumab deruxtecan - Pysician's ChT choice (eribulin, capecitabine, gemcitabine, nab-paclitaxel, or paclitaxel) Treatment of patients with unresectable or metastatic HER2‑low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy DESTINY-Breast04Breast Cancer
Breast Cancer HER2-low DESTINY-Breast04 Darolutamide ADT ((androgen deprivation therapy) + docetaxel ADT + Docetaxel + placebo For adult patients with metastatic hormone-sensitive prostate cancer (mHSPC). ARASENSGenitourinary Cancers
Prostate cancer - ARASENS Camrelizumab Gemcitabine + cisplatin Placebo + gemcitabine + cisplatin First-line treatment of recurrent or metastatic nasopharyngeal carcinoma CAPTAIN-1stHead and neck cancer
Nasopharyngeal carcinoma - CAPTAIN-1st Toripalimab Gemcitabine + cisplatin Placebo + gemcitabine + cisplatin Toripalimab with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent, locally advanced nasopharyngeal carcinoma (NPC) JUPITER-02Head and neck cancer
Nasopharyngeal carcinoma - JUPITER-02 Atezolizumab - Single arm (Phase II) Patients with locally advanced or metastatic UC who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression ≥5% IMvigor210 – Cohort 1Genitourinary Cancers
Urothelial Carcinoma PD-L1 expression ≥5% IMvigor210 – Cohort 1 Pembrolizumab - Single arm Patients with locally advanced or metastatic UC who are not eligible for any platinum-containing ChT KEYNOTE-052Genitourinary Cancers
Urothelial Carcinoma - KEYNOTE-052 Selpercatinib - Single arm (Phase I/II) EMA/FDA: Treatment for adult patients with locally advanced or metastatic solid tumors with a rearranged during transfection (RET) gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options (other than non-small cell lung cancer and thyroid cancer). LIBRETTO-001Tumour agnostic
- RET gene fusion LIBRETTO-001 Tremelimumab Durvalumab Sorafenib EMA: Treatment for adult patients in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma - FDA: Treatment for adult patients in combination with durvalumab with unresectable hepatocellular carcinoma HIMALAYAGastrointestinal Cancers
Hepatobiliary Cancers - Hepatocellular Carcinoma - HIMALAYA Pembrolizumab - Single arm (Phase II) For patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation. KEYNOTE-629Skin Cancers
Cutaneous Squamous Cell Carcinoma - KEYNOTE-629 Cemiplimab - Single arm (Phase II) For the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mCSCC or laCSCC) who are not candidates for curative surgery or curative radiation R2810-ONC-1423/R2810-ONC-1540Skin Cancers
Cutaneous Squamous Cell Carcinoma - R2810-ONC-1423/R2810-ONC-1540 Cemiplimab - Investigator's choice of ChT Indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy EMPOWER-Cervical 1Gynaecological Malignancies
Cervical Cancer - EMPOWER-Cervical 1 Tremelimumab Durvalumab and platinum-based ChT Platinum-based ChT EMA: First-line treatment of tremelimumab in combination with durvalumab and platinum-based chemotherapy (ChT) for adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations - FDA: Tremelimumab in combination with durvalumab and platinum-based ChT for adult patients with metastatic NSCLC with no EGFR mutation or ALK genomic tumor aberrations. POSEIDONThoracic Malignancies
Non-small-cell Lung Cancer - POSEIDON Abemaciclib - Single arm Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer with disease progression following ET and prior ChT in the metastatic setting MONARCH 1Breast Cancer
Breast Cancer HR+ HER2- MONARCH 1 Bevacizumab Capecitabine Placebo + capecitabine First-line treatment of patients with metastatic breast cancer in whom treatment with other ChT options, including taxanes or anthracyclines, is not considered appropriate. Patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with bevacizumab–capecitabine RIBBON-1Breast Cancer
Breast Cancer - RIBBON-1 Olaparib Abiraterone + prednisone or prednisolone Placebo + abiraterone + prednisone or prednisolone EMA: Olaparib is indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mCRPC in whom chemotherapy is not clinically indicated. FDA: olaparib with abiraterone and prednisone (or prednisolone) for adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). PROpelGenitourinary Cancers
Prostate cancer - PROpel Relatlimab Nivolumab Nivolumab First line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell PD-L1 expression <1%. RELATIVITY-047Skin Cancers
Cutaneous Melanoma PD-L1 expression <1% RELATIVITY-047 Adagrasib - Single arm Indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression after at least one prior systemic therapy KRYSTAL-1Thoracic Malignancies
Non-small-cell Lung Cancer KRAS G12C KRYSTAL-1 Abemaciclib Standard endocrine therapy (aromatase inhibitors and/or antiestrogens with or without ovarian suppression) Standard endocrine therapy Adjuvant treatment of adult patients with hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence monarchEBreast Cancer
Early Breast Cancer HR+ HER2- node-positive monarchERetroSearch is an open source project built by @garambo | Open a GitHub Issue
Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo
HTML:
3.2
| Encoding:
UTF-8
| Version:
0.7.3